{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,5,15]],"date-time":"2022-05-15T02:26:07Z","timestamp":1652581567407},"reference-count":26,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1016\/j.lungcan.2004.05.015","type":"journal-article","created":{"date-parts":[[2004,8,10]],"date-time":"2004-08-10T19:55:49Z","timestamp":1092167749000},"page":"121-127","source":"Crossref","is-referenced-by-count":12,"title":["Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer"],"prefix":"10.1016","volume":"47","author":[{"given":"Marcus A.","family":"Neubauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David H.","family":"Garfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul R.","family":"Kuerfler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert N.","family":"Raju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah L.","family":"Lindquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward W.","family":"Soo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myrna","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristi A.","family":"Boehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Asmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2004.05.015_BIB1","unstructured":"Glassberg AB, Cornett P. Lung: non-small cell. In: Dollinger M, Rosenbaum EH, Cable G, editors. Everyone\u2019s guide to cancer therapy. Kansas City, MO: Somerville House Books Limited;1994:469\u201375."},{"key":"10.1016\/j.lungcan.2004.05.015_BIB2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0140-6736(93)91882-M","article-title":"Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis","volume":"342","author":"Souquet","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB3","doi-asserted-by":"crossref","unstructured":"Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 1995;311:899\u2013909.","DOI":"10.1136\/bmj.311.7010.899"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB4","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1378\/chest.106.3.861","article-title":"Chemotherapy vs. supportive care in advanced non-small cell lung cancer. Results of a meta-analysis of the literature","volume":"106","author":"Marino","year":"1994","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB5","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1200\/JCO.1993.11.10.1866","article-title":"Chemotherapy for advanced non-small cell lung cancer: how much benefit is enough?","volume":"11","author":"Grilli","year":"1993","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB6","first-page":"1087","article-title":"New chemotherapeutic agents prolong survival and improve quality of life in non-small lung cancer: a review of the literature and future directions","volume":"4","author":"Bunn","year":"1998","journal-title":"Clin. Cancer Res"},{"issue":"3 Suppl 9","key":"10.1016\/j.lungcan.2004.05.015_BIB7","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/sonc.2001.24601","article-title":"Review of two phase II randomized trials of single-agent docetaxel in previously treated advanced non-small cell lung cancer","volume":"28","author":"Lynch","year":"2001","journal-title":"Semin. Oncol"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB8","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1023\/A:1012208711013","article-title":"Clinical-benefit response in advanced non-small-cell lung cancer: a multicentre prospective randomised phase III study of single agent gemcitabine versus cisplatin-vindesine","volume":"12","author":"Vansteenkiste","year":"2001","journal-title":"Ann. Oncol"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB9","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1200\/JCO.2000.18.12.2354","article-title":"Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group","volume":"18","author":"Fossella","year":"2000","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB10","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1200\/JCO.2000.18.10.2095","article-title":"Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy","volume":"8","author":"Shepherd","year":"2000","journal-title":"J. Clin. Oncol"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0169-5002(00)00094-5","article-title":"A multicenter, randomized, phase III study of docetaxel plus supportive care versus best supportive care in chemotherapy-na\u0131\u0308ve patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC)","volume":"27","author":"Roszkowski","year":"2000","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB12","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/1097-0142(20000715)89:2<328::AID-CNCR17>3.0.CO;2-F","article-title":"Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma","volume":"89","author":"Hainsworth","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB13","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1002\/1097-0142(20011015)92:8<2158::AID-CNCR1558>3.0.CO;2-2","article-title":"Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma","volume":"92","author":"Lilenbaum","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0169-5002(02)00306-9","article-title":"Weekly low-dose docetaxel in advanced non-small cell lung cancer previously treated with two chemotherapy regimens","volume":"39","author":"Petrioli","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB15","unstructured":"WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization, 1979, Offset Publication No. 48."},{"key":"10.1016\/j.lungcan.2004.05.015_BIB16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2307\/2281868","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J. Am. Statistics Assoc"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB17","first-page":"27","article-title":"Docetaxel and gemcitabine combinations in non-small cell lung cancer","volume":"26","author":"Rizvi","year":"1999","journal-title":"Semin. Oncol"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB18","first-page":"19","article-title":"Docetaxel (Taxotere) and gemcitabine in combination therapy","volume":"26","author":"Rizvi","year":"1999","journal-title":"Semin. Oncol"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1023\/A:1008306616994","article-title":"Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabibine: a phase II trial","volume":"12","author":"Spiridonidis","year":"2001","journal-title":"Ann. Oncol"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB20","first-page":"8","article-title":"Docetaxel (Taxotere) and gemcitabine phase I and early phase II studies: results to date and an overview of ongoing studies","volume":"26","author":"van Oosterom","year":"1999","journal-title":"Semin. Oncol"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB21","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1016\/S0140-6736(00)04644-4","article-title":"Platinum-based and non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a randomised multicentre trial","volume":"357","author":"Georgoulias","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0093-7754(01)90221-0","article-title":"Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non-small cell lung cancer","volume":"28","author":"Hainsworth","year":"2001","journal-title":"Semin. Oncol"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0169-5002(00)00212-9","article-title":"Docetaxel in combination with gemcitbine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study","volume":"32","author":"Kakolyris","year":"2001","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB24","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/1097-0142(20000801)89:3<516::AID-CNCR6>3.0.CO;2-9","article-title":"Treatment of patients with advanced nonsmall cell lung carcinoma using docetaxel and gemcitabine plus granulocyte-colony stimulating factor","volume":"89","author":"Henja","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0093-7754(01)90299-4","article-title":"Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer","volume":"28","author":"Georgoulias","year":"2001","journal-title":"Semin. Oncol"},{"key":"10.1016\/j.lungcan.2004.05.015_BIB26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","article-title":"Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer","volume":"346","author":"Schiller","year":"2002","journal-title":"N. Engl. J. Med"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500204002612?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500204002612?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,5]],"date-time":"2019-02-05T00:52:12Z","timestamp":1549327932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500204002612"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["S0169500204002612"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2004.05.015","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2005,1]]}}}